Page 60 - Read Online

Mu et al. Microstructures 2023;3:2023030 https://dx.doi.org/10.20517/microstructures.2023.05 Page 21 of 21

of colloidal calciprotein particles. J Biol Chem 2003;278:13333-41. DOI
208. Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Circ Res 2011;108:1494-
509. DOI PubMed
209. Zebboudj AF, Imura M, Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem
2002;277:4388-94. DOI PubMed
210. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005;97:105-14. DOI PubMed
211. Mckee M, Nanci A. Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: Ultrastructural
distribution and implications for mineralized tissue formation, turnover, and repair. Microsc Res Tech 1996;33:141-64. PubMed
212. McKee MD, Nanci A. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect Tissue Res
1996;35:197-205. DOI PubMed
213. Oikonomaki T, Papasotiriou M, Ntrinias T, et al. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis
patients: a 1-year follow-up randomized trial. Int Urol Nephrol 2019;51:2037-44. DOI
214. Eastell R, Walsh JS, Watts NB, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011;49:82-8. DOI PubMed
215. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological
calcification in vivo. Science 1969;165:1264-6. DOI PubMed
216. der Sluis IM, Boot AM, Vernooij M, Meradji M, Kroon AA. Idiopathic infantile arterial calcification: clinical presentation, therapy
and long-term follow-up. Eur J Pediatr 2006;165:590-3. DOI PubMed
217. Persy V, De Broe M, Ketteler M. Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels?
Kidney Int 2006;70:1537-8. DOI PubMed
218. Shiraishi N, Kitamura K, Miyoshi T, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis)
by etidronate disodium. Am J Kidney Dis 2006;48:151-4. DOI
219. Jansen RS, Duijst S, Mahakena S, et al. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization
inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol 2014;34:1985-9. DOI
PubMed PMC
220. Li Q, Huang J, Pinkerton AB, et al. Inhibition of tissue-nonspecific alkaline phosphatase attenuates ectopic mineralization in the
Abcc6(-/-) mouse model of PXE but not in the enpp1 mutant mouse models of GACI. J Invest Dermatol 2019;139:360-8. DOI
PubMed PMC
221. Pomozi V, Brampton C, van de Wetering K, et al. Pyrophosphate supplementation prevents chronic and acute calcification in
ABCC6-deficient mice. Am J Pathol 2017;187:1258-72. DOI PubMed PMC
222. Zhao J, Kingman J, Sundberg JP, Uitto J, Li Q. Plasma PPi deficiency is the major, but not the exclusive, cause of ectopic
mineralization in an Abcc6(-/-) mouse model of PXE. J Invest Dermatol 2017;137:2336-43. DOI PubMed PMC
223. Garti N, Tibika F, Sarig S, Perlberg S. The inhibitory effect of polymeric carboxylic amino-acids and urine on calcium oxalate
crystallization. Biochem Biophys Res Commun 1980;97:1154-62. DOI PubMed
224. Kleinman JG, Alatalo LJ, Beshensky AM, Wesson JA. Acidic polyanion poly(acrylic acid) prevents calcium oxalate crystal
deposition. Kidney Int 2008;74:919-24. DOI PubMed PMC
225. Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL. The calcium oxalate crystal growth inhibitor protein produced by
mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 1992;7:1029-36. DOI PubMed
226. Wesson JA, Johnson RJ, Mazzali M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in
renal tubules. J Am Soc Nephrol 2003;14:139-47. DOI
227. Cohen GF, Vyas NS. Sodium thiosulfate in the treatment of calciphylaxis. J Clin Aesthet Dermatol 2013;6:41-4. PubMed PMC
228. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous
haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 2005;20:1260-2. DOI PubMed
229. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J
Kidney Dis 2004;43:1104-8. DOI PubMed
230. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985;23:63-7. PubMed
231. Sun XY, Xu M, Ouyang JM. Effect of crystal shape and aggregation of calcium oxalate monohydrate on cellular toxicity in renal
epithelial cells. ACS Omega 2017;2:6039-52. DOI PubMed PMC
232. Bazin D, Chevallier P, Matzen G, Jungers P, Daudon M. Heavy elements in urinary stones. Urol Res 2007;35:179-84. DOI PubMed
233. Meyer J, Angino E. The role of trace metals in calcium urolithiasis. Invest Urol 1977;14:347-50. PubMed
234. Muñoz JA, Valiente M. Effects of trace metals on the inhibition of calcium oxalate crystallization. Urol Res 2005;33:267-72. DOI
PubMed
235. Atakan IH, Kaplan M, Seren G, Aktoz T, Gül H, Inci O. Serum, urinary and stone zinc, iron, magnesium and copper levels in
idiopathic calcium oxalate stone patients. Int Urol Nephrol 2007;39:351-6. DOI
236. Levy RJ, Schoen FJ, Flowers WB, Staelin ST. Initiation of mineralization in bioprosthetic heart valves: studies of alkaline
phosphatase activity and its inhibition by AlCl or FeCl preincubations. J Biomed Mater Res 1991;25:905-35. DOI PubMed
3 3
237. Ali SY. Apatite-type crystal deposition in arthritic cartilage. Scan Electron Microsc 1985;Pt 4:1555-66. PubMed
238. Usai D, Maritan L, Dal Sasso G, et al. Late pleistocene/early holocene evidence of prostatic stones at Al khiday cemetery, central
sudan. PLoS One 2017;12:e0169524. DOI PubMed PMC